Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1719200

registered interest
date	20/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Licensing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what flexibility (a) NICE and (b) NHS England have to approve for use drugs that (i) are used in combination with other drugs, (ii) are used for various (A) conditions and (B) lines of treatment and (iii) provide significant benefits for some but not all patients; and what tools those organisations use to ensure the effectiveness of such appraisals.
tabling member constituency	Birmingham, Yardley
tabling member printed	Jess Phillips
uin	27051
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new licensed medicines, and significant licence extensions for existing medicines, should be routinely funded by the NHS. The NICE is able to recommend most new medicines for use by the NHS, including as a result of commercial agreements negotiated between NHS England and the company, in line with the commercial framework for new medicines.</p><p>The NICE develops its guidance in line with its published health technology evaluations manual, which sets out the circumstances in which its Appraisal Committees are able to apply flexibility in the evaluation of specific treatments. The NICE is, for example, able to apply a modifier in the evaluation of medicines for severe diseases that means that its committees are able to recommend medicines at a higher cost-effectiveness threshold than for less severe diseases. The NICE appraises combination therapies using the same methods that it uses for appraising single drug therapies.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/05/2024 16:08:56 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4370 label Biography information for Jess Phillips

1719225

registered interest
date	20/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Social Services: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will make an estimate of the number and proportion of working-aged adults that receive adult social care that are (a) self-funded and (b) funded by their (i) local authority and (ii) Integrated Care Board.
tabling member constituency	South Swindon
tabling member printed	Sir Robert Buckland
uin	27033
answer	answer is ministerial correction date of answer 24/05/2024 answer text <p>Data from the adult social care short and long-term collection shows that, as of 31 March 2023, 258,940 people aged 18 to 64 years old were receiving long-term support commissioned via, although not necessarily funded by, their local authority. The Department does not hold data centrally on working age adults who are self-funded, or on integrated care board funded care for working age adults.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 24/05/2024 08:38:11 answering member 4527 label Biography information for Helen Whately
tabling member	4106 label Biography information for Sir Robert Buckland

1719226

registered interest
date	20/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Social Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will make an estimate of the number and proportion of working-aged adults that have not received adult social care following an approach to their local authority in the last 12 months.
tabling member constituency	South Swindon
tabling member printed	Sir Robert Buckland
uin	27034
answer	answer is ministerial correction date of answer 24/05/2024 answer text <p>A total of 611,590 adults aged between 18 and 64 years old made requests for social care support in 2022/23. Of these, 216,135, or 35.3%, did not receive support from their local authority. Local authorities are responsible for assessing individuals’ care and support needs and, where eligible, for meeting those needs. Where a person is assessed as having eligible care and support needs, the local authority should then carry out a financial assessment to determine what they can afford to contribute towards the cost of meeting their care need. Where individuals do not meet the eligibility threshold, they can get support from their local authorities in making their own arrangements for care services, as set out in the Care Act 2014.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 24/05/2024 08:35:33 answering member 4527 label Biography information for Helen Whately
tabling member	4106 label Biography information for Sir Robert Buckland

1719241

registered interest
date	20/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Department of Health and Social Care: Redundancy Pay
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether any ministerial redundancy payments have been repaid to her Department since 2019.
tabling member constituency	Ellesmere Port and Neston
tabling member printed	Justin Madders
uin	27086
answer	answer is ministerial correction date of answer 24/05/2024 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/05/2024 11:46:44 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4418 label Biography information for Justin Madders

1719284

registered interest
date	20/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Enzyme Replacement Therapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help ensure the adequacy of access to (a) Creon and (b) other drugs that contain pancreatic enzymes for patients after pancreatic surgery.
tabling member constituency	Broxbourne
tabling member printed	Sir Charles Walker
uin	26982
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>We are aware of supply issues with three pancreatic enzyme replacement therapies: Creon 10,000 gastro-resistant capsules; Creon 25,000 gastro-resistant capsules; and Nutrizym 22 gastro-resistant capsules. We understand that these are due to limited availability of active pharmaceutical ingredients, and manufacturing constraints in producing the volumes required to meet demand. The Department has issued guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products to ask that they expedite deliveries and increase production forecasts, and to confirm that they are taking action to address the root causes of the issues, to ensure continuity of supply. We are also working with specialist importers to source unlicensed imports from abroad.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/05/2024 15:24:29 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1493 label Biography information for Sir Charles Walker

1719288

registered interest
date	20/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ophthalmic Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the oral contribution of the hon. Member for Strangford on 30 April 2024, Official Report, columns 49WH and 50WH, what assessment she has made of the implications for her policies of the deployment of combined cataract and glaucoma procedures in independent sector treatment centres.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	27040
answer	answer is ministerial correction date of answer 24/05/2024 answer text <p>Combined treatment for glaucoma and cataracts can already be considered when clinically appropriate, taking into account the patient’s wishes and the best available evidence. However, glaucoma is a chronic condition that requires long-term management and monitoring. For patient safety, all glaucoma or ocular hypertension surgery should be performed within units that are providing the full range of services, including diagnosing, treating, and monitoring patients. This also includes offering a full range of medical and surgical treatments that can include drops, laser treatments, and a full range of surgical procedures. This ensures that patients receive the right care, appropriate for the stage and type of glaucoma, and that inappropriate surgical interventions are not undertaken that compromise the long-term management of the patient’s condition.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom grouped question UIN 27041 27042 question first answered 24/05/2024 09:53:04 answering member 4117 label Biography information for Andrea Leadsom
tabling member	4131 label Biography information for Jim Shannon

1719289

registered interest
date	20/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ophthalmic Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the oral contribution of the hon. Member for Strangford on 30 April 2024, Official Report, columns 49WH and 50WH, what assessment she has made of the potential impact of an increase in the deployment of combined cataract and glaucoma procedures in independent sector treatment centres on (a) public spending and (b) patient wellbeing.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	27041
answer	answer is ministerial correction date of answer 24/05/2024 answer text <p>Combined treatment for glaucoma and cataracts can already be considered when clinically appropriate, taking into account the patient’s wishes and the best available evidence. However, glaucoma is a chronic condition that requires long-term management and monitoring. For patient safety, all glaucoma or ocular hypertension surgery should be performed within units that are providing the full range of services, including diagnosing, treating, and monitoring patients. This also includes offering a full range of medical and surgical treatments that can include drops, laser treatments, and a full range of surgical procedures. This ensures that patients receive the right care, appropriate for the stage and type of glaucoma, and that inappropriate surgical interventions are not undertaken that compromise the long-term management of the patient’s condition.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom grouped question UIN 27040 27042 question first answered 24/05/2024 09:53:04 answering member 4117 label Biography information for Andrea Leadsom
tabling member	4131 label Biography information for Jim Shannon

1719290

registered interest
date	20/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ophthalmic Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the oral contribution of the hon. Member for Strangford on 30 April 2024, Official Report, columns 49WH and 50WH, what steps she plans to take to increase the deployment of combined cataract and glaucoma procedures.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	27042
answer	answer is ministerial correction date of answer 24/05/2024 answer text <p>Combined treatment for glaucoma and cataracts can already be considered when clinically appropriate, taking into account the patient’s wishes and the best available evidence. However, glaucoma is a chronic condition that requires long-term management and monitoring. For patient safety, all glaucoma or ocular hypertension surgery should be performed within units that are providing the full range of services, including diagnosing, treating, and monitoring patients. This also includes offering a full range of medical and surgical treatments that can include drops, laser treatments, and a full range of surgical procedures. This ensures that patients receive the right care, appropriate for the stage and type of glaucoma, and that inappropriate surgical interventions are not undertaken that compromise the long-term management of the patient’s condition.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom grouped question UIN 27040 27041 question first answered 24/05/2024 09:53:04 answering member 4117 label Biography information for Andrea Leadsom
tabling member	4131 label Biography information for Jim Shannon

1719292

registered interest
date	20/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prince's Trust: Contracts
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Minister without Portfolio's article of 12 May 2024 in The Sunday Telegraph, when her Department is expected to terminate its contract with the Prince's Trust, order reference C191156; and whether a notice period is required under the provisions of clause 10.2.2 of that contract.
tabling member constituency	Islington South and Finsbury
tabling member printed	Emily Thornberry
uin	26990
answer	answer is ministerial correction date of answer 24/05/2024 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Dissolution.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/05/2024 14:03:28 answering member 4044 label Biography information for Andrew Stephenson previous answer version 36822 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
tabling member	1536 label Biography information for Emily Thornberry

1719325

registered interest
date	20/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hospices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential impact of hospice services on trends in the level of hospital admissions in (a) Lewisham and (b) England.
tabling member constituency	Lewisham West and Penge
tabling member printed	Ellie Reeves
uin	27128
answer	answer is ministerial correction date of answer 24/05/2024 answer text <p>The Department does not hold data that would enable us to make an assessment of the potential impact of hospice services on trends in the level of hospital admissions in Lewisham or England.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 24/05/2024 08:37:03 answering member 4527 label Biography information for Helen Whately
tabling member	4620 label Biography information for Ellie Reeves